Vaccination-Induced Autoimmune Vitiligo Is a Consequence of Secondary Trauma to the Skin

Cancer Research

Volumn 64, Issue 4, 2004, Pages 1509-1514

  Lane, Cecilia ^a   Leitch, Jaina ^a   Tan, Xiaohua ^a   Hadjati, Jamishid ^a   Bramson, Jonathan L ^a   Wan, Yonghong ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; FREUND ADJUVANT; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG EFFICACY; DRUG POTENCY; GENE; HUMAN MELANOMA ANTIGEN TYROSINE RELATED PROTEIN 2 GENE; HUMORAL IMMUNITY; IMMUNITY; IMMUNIZATION; INFLAMMATION; INTERMETHOD COMPARISON; MOUSE; MURINE MELANOMA ANTIGEN TYROSINE RELATED PROTEIN 2 GENE; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; SKIN INJURY; VACCINATION; VACCINE INDUCED VITILIGO; VIRUS RECOMBINANT; VITILIGO;

ADENOVIRIDAE; ANIMALS; AUTOIMMUNE DISEASES; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; INTRAMOLECULAR OXIDOREDUCTASES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SKIN; VACCINATION; VITILIGO;

EID: 1242293633     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3227     Document Type: Article

References (39)

1. Pardoll, D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol., 21: 807-839, 2003.
2. Engelhard, V. H., Bullock, T. N., Colella, T. A., Sheasley, S. L., and Mullins, D. W. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol. Rev., 188: 136-146, 2002.
3. Ramirez-Montagut, T., Turk, M. J., Wolchok, J. D., Guevara-Patino, J. A., and Houghton, A. N. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene, 22: 3180-3187, 2003.
4. Steitz, J., Bruck, J., Gambotto, A., Knop, J., and Tuting, T. Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. Gene Ther., 9: 208-213, 2002.
5. Bronte, V., Apolloni, E., Ronca, R., Zamboni, P., Overwijk, W. W., Surman, D. R., Restifo, N. P., and Zanovello, P. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res., 60: 253-258, 2000.
6. Hirschowitz, E. A., Leonard, S., Song, W., Ferris, B., Leopold, P. L., Lewis, J. J., Bowne, W. B., Wang, S., Houghton, A. N., and Crystal, R. G. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther., 5: 975-983, 1998.
7. + T lymphocytes. Proc. Natl. Acad. Sci. USA, 96: 2982-2987, 1999.
8. Overwijk, W. W., Tsung, A., Irvine, K. R., Parkhurst, M. R., Goletz, T. J., Tsung, K., Carroll, M. W., Liu, C., Moss, B., Rosenberg, S. A., and Restifo, N. P. gp100/pme1 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med., 188: 277-286, 1998.
9. Gold, J. S., Ferrone, C. R., Guevara-Patino, J. A., Hawkins, W. G., Dyall, R., Engelhorn, M. E., Wolchok, J. D., Lewis, J. J., and Houghton, A. N. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J. Immunol., 170: 5188-5194, 2003.
10. Bowne, W. B., Srinivasan, R., Wolchok, J. D., Hawkins, W. G., Blachere, N. E., Dyall, R., Lewis, J. J., and Houghton, A. N. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med., 190: 1717-1722, 1999.
11. Wan, Y., Bramson, J., Pilon, A., Zhu, Q., and Gauldie, J. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Cancer Res., 60: 3247-3253, 2000.
12. Gilboa, E. The risk of autoimmunity associated with tumor immunotherapy. Nat. Immunol., 2: 789-792, 2001.
13. Treka, J., Moroi, Y., Clynes, R. A., Goldberg, S. M., Bergtold, A., Perales, M. A., Ma, M., Ferrone, C. R., Carroll, M. C., Ravetch, J. V., and Houghton, A. N. Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity, 16: 861-868, 2002.
14. Bramson, J., Dayball, K., Evelegh, C., Wan, Y. H., Page, D., and Smith, A. Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Ther., 10: 251-260, 2003.
15. Steitz, J., Bruck, J., Steinbrink, K., Enk, A., Knop, J., and Tuting, T. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int. J. Cancer, 86: 89-94, 2000.
16. Ludewig, B., Ochsenbein, A. F., Odermatt, B., Paulin, D., Hengartner, H., and Zinkernagel, R. M. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med., 191: 795-804, 2000.
17. Hurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T., Choi, E. M., Greenberg, N. M., Burg, M. B., and Allison, J. P. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res., 60: 2444-2448, 2000.
18. Fong, L., Ruegg, C. L., Brockstedt, D., Engleman, E. G., and Laus, R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J. Immunol., 159: 3113-3117, 1997.
19. Pardoll, D. M. Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA, 96: 5340-5342, 1999.
20. Nanda, N. K., and Sercarz, E. E. Induction of anti-self-immunity to cure cancer. Cell, 82: 13-17, 1995.
21. Greiner, J. W., Zeytin, H., Anver, M. R., and Schlom, J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res., 62: 6944-6951, 2002.
22. Francini, G., Scardino, A., Kosmatopoulos, K., Lemonnier, F. A., Campoccia, G., Sabatino, M., Pozzessere, D., Petrioli, R., Lozzi, L., Neri, P., Fanetti, G., Cusi, M. G., and Correale, P. High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects. J. Immunol., 169: 4840-4849, 2002.
23. + CTL in vivo. J. Immunol., 167: 5027-5033, 2001.
24. Coles, R. M., Mueller, S. N., Heath, W. R., Carbone, F. R., and Brooks, A. G. Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J. Immunol., 168: 834-838, 2002.
25. Perricone, M. A., Claussen, K. A., Smith, K. A., Kaplan, J. M., Piraino, S., Shankara, S., and Roberts, B. L. Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. Mol. Ther., 1: 275-284, 2000.
26. Meng, W. S., Butterfield, L. H., Ribas, A., Dissette, V. B., Heller, J. B., Miranda, G. A., Glaspy, J. A., McBride, W. H., and Economou, J. S. α-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res., 61: 8782-8786, 2001.
27. Wan, Y., Bramson, J., Carter, R., Graham, F., and Gauldie, J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum. Gene Ther., 8: 1355-1363, 1997.
28. Liu, D. W., Tsao, Y. P., Hsieh, C. H., Hsieh, J. T., Kung, J. T., Chiang, C. L., Huang, S. J., and Chen, S. L. Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J. Virol., 74: 9083-9089, 2000.
29. Rosenberg, S. A., and White, D. E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol., 19: 81-84, 1996.
30. Weber, L. W., Bowne, W. B., Wolchok, J. D., Srinivasan, R., Qin, J., Moroi, Y., Clynes, R., Song, P., Lewis, J. J., and Houghton, A. N. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Investig., 102: 1258-1264, 1998.
31. Hodge, J. W., Grosenbach, D. W., Aarts, W. M., Poole, D. J., and Schlom, J. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res., 9: 1837-1849, 2003.
32. Morgan, D. J., Kreuwel, H. T., Fleck, S., Levitsky, H. I., Pardoll, D. M., and Sherman, L. A. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol., 160: 643-651, 1998.
33. Schreurs, M. W., Eggert, A. A., de Boer, A. J., Vissers, J. L., van Hall, T., Offringa, R., Figdor, C. G., and Adema, G. J. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res., 60: 6995-7001, 2000.
34. Guadagni, F., Roselli, M., Cosimelli, M., Spila, A., Cavaliere, F., Arcuri, R., D'Alessandro, R., Fracasso, P. L., Casale, V., Vecchione, A., Casciani, C. U., Greiner, J. W., and Schlom, J. Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation. Int. J. Cancer, 72: 949-954, 1997.
35. Vonderheide, R. H. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene, 21: 674-679, 2002.
36. Disis, M. L., and Cheever, M. A. HER-2/neu oncogenic protein: issues in vaccine development. Crit. Rev. Immunol., 18: 37-45, 1998.
37. Colella, T. A., Bullock, T. N., Russell, L. B., Mullins, D. W., Overwijk, W. W., Luckey, C. J., Pierce, R. A., Restifo, N. P., and Engelhard, V. H. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J. Exp. Med., 191: 1221-1232, 2000.
38. + T cells. J. Exp. Med., 198: 569-580, 2003.
39. Hara, I., Takechi, Y., and Houghton, A. N. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J. Exp. Med., 182: 1609-1614, 1995.